HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Yangzhou Nanopore Innovative Materials Technology - About the Business Model and the Outlook

Wuxi Biologics (2269 HK) Placement - Thought on Valuation and the Outlook

Pre-IPO Guangzhou Tinci Materials Technology (PHIP Updates) - Some Points Worth the Attention

Equity Capital Markets

<ul>
<li>Akeso has entered into a Placing agreement to issue 20 million new shares at HK$97.76 each, representing a discount of about 6.90% to the previous day’s closing price (HK$105.00)</li>
<li>Launching the Placement a month in advance would obviously cause investors to worry about the FDA results on Nov.14th. Does this indicate that Akeso lacks confidence in the FDA results?</li>
<li>The FDA approval results and subsequent HARMONi-3 data will be the crucial turning point that determines the valuation direction – either to surpass Innovent or fall back to RMB50 billion</li>
</ul>


Akeso has entered into a Placing agreement to issue 20 million new shares at HK$97.76 each, representing a discount of about 6.90% to the previous day’s closing price (HK$105.00)
Launching the Placement a month in advance would obviously cause investors to worry about the FDA results on Nov.14th. Does this indicate that Akeso lacks confidence in the FDA results?
The FDA approval results and subsequent HARMONi-3 data will be the crucial turning point that determines the valuation direction – either to surpass Innovent or fall back to RMB50 billion


Akeso (9926 HK) Placement - The Logic Behind and Thoughts on Valuation